Glucagonoma natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
mNo edit summary
Line 11: Line 11:


== Complications ==
== Complications ==
Complications of glucagonoma include:
* Metastasis:  
* Metastasis:  
**Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis.
**Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis.
Line 29: Line 30:


==Prognosis==
==Prognosis==
Prognosis of glucagonoma depends on the following:
*Whether or not the tumor can be removed by surgery.
*The [[stage of the tumor]], the size of the tumor, whether cancer has [[spread]] outside [[the pancreas]].
*The patient’s general health.
*Whether the tumor has just been diagnosed or has recurred.
*The presence of [[metastasis]] is associated with a particularly poor prognosis among patients with glucagonoma.
*The 10-year event free [[survival rate]] is less than 51.6% with [[metastasis]] and 64.3% without metastasis.
Additionally:
* [[Age]], [[grade]], and distant [[metastases]] are the most significant predictors of survival.
* [[Age]], [[grade]], and distant [[metastases]] are the most significant predictors of survival.
* Five and 10-year survival rates for patients undergoing resection of gastroenteropancreatic [[neuroendocrine tumors]].<ref name="pmid8606627">{{cite journal| author=Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV| title=The glucagonoma syndrome. Clinical and pathologic features in 21 patients. | journal=Medicine (Baltimore) | year= 1996 | volume= 75 | issue= 2 | pages= 53-63 | pmid=8606627 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8606627  }}</ref>
* Five and 10-year survival rates for patients undergoing resection of gastroenteropancreatic [[neuroendocrine tumors]].<ref name="pmid8606627">{{cite journal| author=Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV| title=The glucagonoma syndrome. Clinical and pathologic features in 21 patients. | journal=Medicine (Baltimore) | year= 1996 | volume= 75 | issue= 2 | pages= 53-63 | pmid=8606627 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8606627  }}</ref>
Line 43: Line 53:
  | pmid = 11370794
  | pmid = 11370794
}}</ref>
}}</ref>
Prognosis of glucagonoma depends on the following:
*Whether or not the tumor can be removed by surgery.
*The [[stage of the tumor]], the size of the tumor, whether cancer has [[spread]] outside [[the pancreas]].
*The patient’s general health.
*Whether the tumor has just been diagnosed or has recurred.
*The presence of [[metastasis]] is associated with a particularly poor prognosis among patients with glucagonoma.
*The 10-year event free [[survival rate]] is less than 51.6% with [[metastasis]] and 64.3% without metastasis.


==References==
==References==

Revision as of 14:41, 17 November 2017

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma natural history, complications and prognosis

CDC on Glucagonoma natural history, complications and prognosis

Glucagonoma natural history, complications and prognosis in the news

Blogs on Glucagonoma natural history, complications and prognosis

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D[3]

Overview

If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia. The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis. Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis. Age, grade, and distant metastases are the most significant predictors of survival.

Natural History

Complications

Complications of glucagonoma include:

Prognosis

Prognosis of glucagonoma depends on the following:

  • Whether or not the tumor can be removed by surgery.
  • The stage of the tumor, the size of the tumor, whether cancer has spread outside the pancreas.
  • The patient’s general health.
  • Whether the tumor has just been diagnosed or has recurred.
  • The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma.
  • The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis.

Additionally:

References

  1. K. Chang-Chretien, J. T. Chew & D. P. Judge. "Reversible dilated cardiomyopathy associated with glucagonoma". Heart (British Cardiac Society). 90 (7): e44. doi:10.1136/hrt.2004.036905. PMID 15201270.
  2. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
  3. M. A. Chastain (2001). "The glucagonoma syndrome: a review of its features and discussion of new perspectives". The American journal of the medical sciences. 321 (5): 306–320. PMID 11370794. Unknown parameter |month= ignored (help)

Template:WH Template:WS